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Abstract CRISPR-Cas9 genome engineering has revolutionised high-throughput functional
genomic screens. However, recent work has raised concerns regarding the performance of CRISPR-
Cas9 screens using TP53 wild-type human cells due to a p53-mediated DNA damage response
(DDR) limiting the efficiency of generating viable edited cells. To directly assess the impact of
cellular p53 status on CRISPR-Cas9 screen performance, we carried out parallel CRISPR-Cas9
screens in wild-type and TP53 knockout human retinal pigment epithelial cells using a focused dual
guide RNA library targeting 852 DDR-associated genes. Our work demonstrates that although
functional p53 status negatively affects identification of significantly depleted genes, optimal
screen design can nevertheless enable robust screen performance. Through analysis of our own
and published screen data, we highlight key factors for successful screens in both wild-type and
p53-deficient cells.
Introduction
CRISPR-Cas9 genome engineering technologies have transformed cell biology, particularly high
throughput functional genomic screens (Wang et al., 2015; Shalem et al., 2014; Shalem et al.,
2015; Smith et al., 2017) . Pooled CRISPR-Cas9 cell viability screens have been successfully
employed in determining gene essentiality (Hart et al., 2015), identifying genetic interactions
(Chan et al., 2019) and assessing drug sensitivities across various genetic backgrounds (Han et al.,
2017). A number of factors influence CRISPR-Cas9 screen performance, including cellular back-
ground. In particular, recent reports concerning technical difficulties in CRISPR-Cas9 genome editing
in p53-proficient cells, have brought into question the suitability of p53-proficient cell lines for high
throughput CRISPR-Cas9 genetic screens (Haapaniemi et al., 2018; Ihry et al., 2018).
TP53, encoding p53, acts as a master regulator of cell-cycle checkpoint activation (Kastan et al.,
1991), cellular senescence (Shay et al., 1991) and induction of apoptosis in response to DNA dam-
age (Clarke et al., 1993; Lowe et al., 1993; Lakin and Jackson, 1999). TP53 is arguably the most
important tumour suppressor gene, with loss of function mutations in up to 50% of human cancers
(Bouaoun et al., 2016). Consequently, the p53 status of a cell line, either wild-type (proficient) or
mutant (deficient), can be an important factor in determining the suitability of a cellular model, and
hence is an important consideration in design of high throughput genetic screens.
Generation of DNA double strand breaks (DSBs) induces p53-dependent cell-cycle arrest in nor-
mal fibroblasts (Di Leonardo et al., 1994), and most CRISPR-Cas9 genome editing approaches rely
on DSB generation to achieve efficient editing (Jinek et al., 2012). Recent work has shown that
CRISPR-Cas9-associated DSBs in hPSCs (human pluripotent stem cells) induce a p53-mediated apo-
ptotic response, leading to high levels of toxicity and reduced editing efficiency in this background
(Ihry et al., 2018). Furthermore, a similar p53-mediated DSB response in wild-type retinal pigment
epithelial (RPE-1) cells reportedly severely impaired identification of essential genes in a CRISPR-
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Cas9 screen when compared to RPE-1 TP53 knockout (TP53KO) cells (Haapaniemi et al., 2018). In
contrast, analysis of data from a small number of additional screens in p53 wild-type RPE-1 cells has
shown that performance of successful CRISPR screens, as determined by essential gene identification
and enrichment of expected targets, is possible in this cellular background (Brown et al., 2019).
This controversy is confounded by the complexity of variation in experimental design between
screens with a lack of controlled parallel experiments. To provide more definitive insights into this
important debate, we performed parallel CRISPR-Cas9 screens in paired wild-type and TP53KO cell
lines, thereby minimising additional confounding factors that can preclude accurate screen
comparisons.
Results and discussion
We carried out parallel screens, in wild-type and TP53KO RPE-1 cells with two independent Cas9-
expressing monoclonal populations for each genetic background, selected based on p53 status and
high Cas9 cutting efficiency (Figure 1—figure supplement 1). To facilitate high screen sensitivity
and in-depth interrogation of p53-mediated responses to CRISPR-Cas9-associated DSBs, we
designed a bespoke dual guide RNA library targeting 852 DDR-related genes, with 112 olfactory
receptor genes included as non-essential gene controls and 14 sequence-scrambled negative con-
trols (Supplementary file 1). The library was manually curated to include established DDR compo-
nents, putatively DDR related interactors, and a considerable number of bioinformatically-associated
DDR factors. Moreover, the smaller size of this library compared to a whole genome library enabled
high guide representation (>1000 x) to be maintained throughout the screen, minimising the impact
of this key factor on screen sensitivity (Miles et al., 2016). In addition, our library incorporated a
dual guide RNA vector design (Erard et al., 2017) to increase the frequency of functional knockout
events in transduced cells compared to the canonical single guide RNA (sgRNA) approach. We
eLife digest The invention of CRISPR-Cas9 genome editing has unlocked a greater
understanding of the human genome. Researchers can use this system to make targeted cuts in any
gene in the genome, forcing the cell to perform a rapid repair at the cut site. These repairs often
introduce mutations into the damaged area, adding or removing DNA letters and disrupting the
gene. This allows researchers to study what happens to cells when specific genes are missing, which
can help to uncover what each gene is for.
One of the most comprehensive ways to use this technique is to perform a CRISPR-Cas9 screen,
which disrupts each gene in the genome one by one. For a CRISPR-Cas9 screen to work well, a cell
needs to survive the cuts to its genome. But there is a crucial gene that can stop this happening.
Often described as the ’guardian of the genome’, this gene codes for a protein called p53, a tumour
suppressor that helps to stop a cell turning cancerous when its DNA becomes damaged. This
protein activates when the cell senses a cut in its genetic material and can kill the cell if it fails to
make a successful repair.
Recent work has shown that the presence of a working copy of the gene for the p53 protein
might limit the ability of CRISPR-Cas9 to edit genes. But the evidence was inconclusive. So, Bowden,
Morales-Juarez et al. performed two parallel CRISPR-Cas9 screens in human cells with and without
p53 to find out more. This revealed that CRISPR-Cas9 can inactivate genes in both normal cells and
cells lacking the p53 protein, but that it works better in cells without p53. This was because, when
p53 was active, the cells initiated a protective response against the CRISPR-Cas9 cuts. This changed
the patterns of genes successfully inactivated by the screen, but it did not make the results
unusable. Careful experimental design and thorough data analysis made it possible to get useful
results even in cells with functional p53 protein.
The gene for p53 has mutations in around half of human cancers. So, understanding how it
affects CRISPR-Cas9 screens could influence the design of future experiments. It is possible that the
effects of the p53 protein could vary from cell type to cell type, and with different p53 mutations.
Comparisons like the one performed here could help to further unpick how the cell’s DNA repair
systems might interfere with future CRISPR experiments.
Bowden et al. eLife 2020;9:e55325. DOI: https://doi.org/10.7554/eLife.55325 2 of 12
Short report Genetics and Genomics
reasoned that a vector generating two DSBs per cell may increase detection of differences in screen
sensitivity due to variation in DSB responses between genetic backgrounds. Thus, the custom DDR
library enables interrogation of p53-mediated DDR events, a cell’s overall responses to DSBs, and
the fitness effects of inactivating DDR-related genes. Screens were executed as depicted in Figure 1,
and relative enrichments and depletions of gene knockouts in the edited cell populations were
determined from guide read counts generated by next-generation Illumina DNA sequencing
(Supplementary file 2) using the program MAGeCK (Li et al., 2014; Supplementary file 3).
In our screens, depletion of core essential genes (as defined by Hart et al., 2017) was clearly evi-
dent in both wild-type and TP53KO backgrounds (Figure 2A and Figure 2—figure supplement 1A).
Due to the conservative nature of this essential gene list, additional genes with significant depletions
were also identified in both cell lines (Supplementary file 3). A receiver operating characteristic
(ROC) curve showing the classification of essential versus non-essential genes by gene depletion
p-value ranks (calculated by MAGeCK) (Figure 2B) demonstrated good performance of both
screens. Nevertheless, the TP53KO screen slightly outperformed the wild-type screen at both har-
vesting timepoints in terms of detection of essential genes by rank.
When the significance of gene depletions was considered, we found that essential genes were
much more likely to have low adjusted p-values (q-values) in the TP53KO background, compared to
wild-type. In addition, we observed that the day 19 timepoint outperformed the day 15 timepoint,
detecting increased numbers of essential genes at a given significance threshold (Figure 2C and Fig-
ure 2—figure supplement 1B). The underlying basis behind this differential sensitivity to identifying
essential genes lies in the magnitude of the phenotypic effect observed for each guide. While log
fold changes (LFCs) across non-core essential (‘not essential’) genes were not significantly different
between the two genetic backgrounds (p=0.60), LFCs for core essential genes were significantly
lower in the TP53KO screens compared to screens in TP53 wild-type settings (p=0.0010) (Figure 2D),
consistent with wild-type cells initiating a p53-mediated response to Cas9-induced DSBs. This would
inhibit the proliferation rates of all transduced cells during the course of the screens, leading to
smaller LFCs and a narrower distribution of guides within the population, with a consequent reduc-
tion in genes with significant depletion scores. Similar results were seen in our analyses of day 15
samples (Figure 2—figure supplement 1C).
The impact of the p53-mediated response is also evident when comparing screen results from dif-
ferential enrichment and depletion of genes between the two genetic backgrounds (Figure 2E). As
Figure 1. Experimental set-up of parallel CRISPR-Cas9 screens in wild-type (WT) and TP53 knockout(TP53KO) RPE-1 cells. Cells were infected at a low
multiplicity of infection (MOI=0.3). An initial sample was harvested 48 hours after infection. Subsequently, transduced cells were selected with
puromycin and harvested at days 15 and 19. Guide RNA (gRNA) representations were evaluated by extraction of genomic DNA from surviving cells,
PCR amplification of barcodes, and next-generation sequencing. MAGeCK (Li et al., 2014) was used to determine the relative depletion and
enrichment of genes in later samples compared to the 48-hour samples.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Validation of RPE-1 clones used in the screens.
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Figure 2. Comparison of CRISPR-Cas9 screens in wild-type (WT) and TP53 knockout(TP53KO) RPE-1 cells demonstrates the impact of p53 on screen
performance. (A) Mean log2 fold change (LFC) in guide abundance per gene, and significance of this change, from day 3 to day 19 of the experiment.
The q-values are false discovery rates (FDR) given by MAGeCK. (B) Receiver operating characteristic curves of MAGeCK p-values, discriminating
between genes classified as core essential by Hart et al. (2017) and other genes. (C) Number of core essential genes with q-value less than the range
of values given on the x-axis. (D) Mean LFC of guides targeting core essential and not core essential genes (Day 19 samples). Paired t-tests were used
to test core essential or not essential genes between cell lines, unpaired t-tests were used within a cell line. (E) Mean LFC of guides targeting core
essential and not core essential genes (Day 19 samples).
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Additional comparisons between wild-type and TP53KO CRISPR-Cas9 screens.
Figure supplement 2. Biological pathway analysis identifies cell-cycle and p53 signalling as the pathways showing enrichment in the wild-type (WT)
compared to TP53KO screens.
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expected, in TP53 wild-type cells, guides targeting TP53 were the most significantly enriched, with
guides targeting other components of the p53 pathway showing the most significant differences
between the two genetic backgrounds. Guides significantly enriched in the TP53 wild-type back-
ground included those targeting CDKN1A that encodes p21, the major downstream mediator of
p53-mediated cell cycle arrest (el-Deiry et al., 1993), and those targeting USP28 that encodes a
deubiquitylating enzyme that acts to stabilise p53 (Zhang et al., 2006; Cuella-Martin et al., 2016).
In contrast, guides targeting genes that were significantly depleted in the wild-type but not the
TP53 knockout background included MDM2 and MDM4, which act as negative regulators of p53.
MDM2 is an E3 ubiquitin ligase that targets p53 for degradation (Haupt et al., 1997), while MDM4
inhibits p53-dependent transcriptional activity (Francoz et al., 2006). SETDB1, which acts via
MDM2, was also enriched in the TP53 wild-type background. This protein forms a complex with p53
and catalyses p53 K370 di-methylation. Attenuation of SETDB1 reduces the level of di-methylation
at this site, leading to increased recognition and degradation of p53 by MDM2 (Fei et al., 2015).
Furthermore, when we assessed the enrichment/depletion of specific biological pathways between
the wild-type and TP53KO backgrounds, cell cycle and p53 signalling were the two pathways that
were enriched (Figure 2—figure supplement 2 and Supplementary file 4).
Genes that are not acting in the p53 pathway were also identified as significantly enriched (e.g.
EP300) or depleted (e.g. CCNA2) at a FDR < 0.1 (Supplementary file 3). EP300 was enriched on
both genetic backgrounds and has an established role as a tumour suppressor through the regula-
tion of the G1/S cell-cycle transition (Ait-Si-Ali et al., 2000). CCNA2, or cyclin A2, was depleted on
both genetic backgrounds as it interacts with both CDK1 and CDK2 to drive S-phase progression
and regulate the G1/S and G2/M phases of the cell-cycle (Pagano et al., 1992). Altogether, these
results demonstrate that despite reduced screen sensitivity in p53-proficient cells, biologically mean-
ingful enrichment and depletion analyses at the individual gene and pathway levels can, when
required, still be performed in TP53 wild-type settings.
To further contextualise the feasibility of performing CRISPR-Cas9 screens in a p53-proficient
background, we analysed our screens with five others performed in TP53 wild-type RPE-1 cells.
When we performed a comparative ROC curve analysis to assess the screens’ abilities to discriminate
between core essential genes and other genes (Figure 3A), this established that the performance of
all screens was similar, with the exception of Haapaniemi et al. (2018) data which underperformed
in the ability to distinguish essential genes. We then examined the distribution of normalised LFCs
for each screen (Figure 3B). This revealed that the core essential genes formed distributions distinct
from those of olfactory receptors and other non-essential genes in all wild-type screens, with the
exception of the Haapaniemi et al. screen where the separation was minimal (the smaller median
LFC in our screen compared to the other four successful screens did not notably hinder our ability to
distinguish essential genes). Taken together, these analyses provide further evidence that CRISPR-
Cas9 screens can be performed successfully in a p53-proficient background. It appears that the Haa-
paniemi et al. screen is an outlier in its inability to robustly detect essential genes, possibly due to
differences in experimental design and execution, and perhaps reflecting relatively low editing effi-
ciency of the polyclonal RPE-1 population used in this screen. This factor strengthens the importance
of carefully selecting clones with high Cas9 editing efficiency and also for the use of biological repli-
cates, to enable recognition of common screen results that are independent of clonal background.
We noted that while the median LFC is higher in the LTRI/MDACC, Hart, UBC and MSKCC
screens, the variance is also increased when compared to ours. Consequently, we interrogated the
relationship between the standard deviation (SD) of the LFCs and the mean LFC values for each of
the wild-type screens. Figure 3C shows that the variance in LFC between guides targeting the same
gene is less in our screen than in these other screens. We speculate that this decrease in variance is
linked to the much higher gRNA representation kept throughout our screen (>1000 x mean gRNA
representation) than in these other screens, although we cannot discard the possibility that the dual-
sgRNA system we used is the cause of this effect. High gRNA representation is relevant for the suc-
cess and reliability of CRISPR-Cas9 screens, with most published recommendations suggesting
screening to at least 200x gRNA representation (Aregger et al., 2019) but ideally >500 x
(Joung et al., 2017). Importantly, high representation must be maintained throughout cell culture
and also in the PCR amplification steps. Sufficient sequencing depth is also essential to maintain the
sensitivity achieved through high gRNA representation. Figure 3D demonstrates the variability in
guide abundance determined by sequencing reads across the screens analysed. The MSKCC screen
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Figure 3. Comparison of wild-type (WT) RPE-1 CRISPR-Cas9 screens highlights important factors in screen design. (A) Receiver operating characteristic
curves of MAGeCK p-values, discriminating between core essential and not core essential genes in TP53 WT cells. (B) Distribution of normalised log2
fold changes (LFCs). The solid lines give kernel density estimates for each distribution, and the dashed line shows the median LFC of the core essential
genes. (C) Mean LFC vs standard deviation (SD) per gene for genes with mean LFC < 0. As the SD is expected to scale with mean LFC, and the LFC
distributions vary between experiments, ordinary least squares regressions were performed to determine the size of the variance across the range of
LFCs. The dashed line shows the line of best fit and the equation for each line is given in the chart. (D) Log2 guide abundance across all screens. Box
plots give median and quartile values.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Reduced variance at higher Log Fold Change is attributable to decreased sequencing reads across multiple guides.
Figure supplement 2. The effect on detection of core essential genes at different sequencing read depths in our screens.
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is the only dataset to show a distribution with a substantial number of zero reads in the final samples,
which accounts for the decreased variance at more negative LFCs in this screen (Figure 3—figure
supplement 1). Through modelling the effect of decreased sequencing depth in our data, we dem-
onstrate that low read counts can notably decrease screen sensitivity (Figure 3—figure supplement
2).
Conclusions
In summary, we present data from parallel screens in TP53 wild-type and TP53KO RPE-1 cells, which
demonstrate that a p53-mediated response does negatively impact the sensitivity of CRISPR-Cas9
screens. The extent of the impact of TP53 status on CRISPR-Cas9 screens might vary depending on
the cell type being studied, including those with loss-of-function mutations in TP53 without being
fully TP53 null. It remains to be established precisely how and to what extent different TP53 muta-
tions, including ‘hotspot’ mutations, might influence CRISPR-Cas9 screen performance. However, we
anticipate that most or all cell lines with an intact TP53 pathway and proper cell-cycle checkpoint
activation would likely recapitulate our findings. Other important factors impacting sensitivity include
the guide RNA library used, the magnitude of guide effects, adequate gRNA representation and suf-
ficient sequencing depth. Selection of high-editing efficiency Cas9-expressing cells is also highly rec-
ommended and use of biological replicates enables identification of clonal variation. Considering
these factors in screen design and execution allows successful CRISPR-Cas9 screens to be carried
out in both p53-proficient and p53-deficient cells, thereby fostering new biological insights.
Materials and methods
Dual-sgRNA library design
A custom dual-sgRNA library was designed to target 852 genes related to the DNA damage
response, 112 olfactory-receptor genes, and 14 sequence scrambled negative controls with a total
of 3404 dual-sgRNAs. The genes targeted by this library include a total of 95 core essential genes.
The sgRNA sequences and pairwise scores were determined using the Croatan scoring algorithm
(Erard et al., 2017). Transomic Technologies selected the top pairs of sgRNAs for each gene and
assigned a distinct barcode to each pair, cloned them into the pCLIP-dual-SFFV-ZsGreen vector, and
packaged them into lentiviral particles ready for transduction. For pooled screening, the viral titre
was determined by exposing cells to a 6-point dose response of the lentiviral stock. The optimal con-
centration of virus to achieve a multiplicity of infection (MOI) of 0.3 was determined by linear regres-
sion analysis.
CRISPR-Cas9 screens
CRISPR-Cas9 screens were performed using the custom dual-sgRNA DNA damage response library
outlined above. Biological duplicates (two independently isolated Cas9-expressing clones) of wild-
type and TP53KO RPE-1 cells were transduced at a MOI of 0.3 and >1,000 fold coverage of the
library. The following day, cells were cultured with puromycin to select for the transductants for 12
additional days. Surviving cells from each biological replicate were harvested prior to puromycin
selection (day 3), and at day 15 and day 19 after initial transduction. Subsequently, the genomic
DNA (gDNA) was isolated using TAIL buffer (17 mM Tris pH 7.5, 17 mM EDTA, 170 mM NaCl,
0.85% SDS, and 1 mg/mL Proteinase K) and subjected to 24 PCR reactions with custom indexed pri-
mers designed to amplify the barcode within the lentiviral backbone and append Illumina adapter
sequences. Finally, the PCR products were purified (QIAquick PCR Purification kit, Qiagen), multi-
plexed, and sequenced on an Illumina HiSeq1500 system. Genes enriched or depleted in the day 15
and day 19 samples compared to the day 3 samples were determined using MAGeCK v0.5.9.2
(Li et al., 2014).
Cell culture
RPE-1 TP53 wild-type and TP53KO cells were cultured in DMEM/F-12 media (Dulbecco’s Modified
Eagle Medium: Nutrient Mixture Ham’s F-12, Sigma-Aldrich) supplemented with 17 mL of 7.5%
NaHCO3 (Sigma-Aldrich) per 500 mL, 10% (v/v) foetal bovine serum (FBS, BioSera), 100 U/mL peni-
cillin, 100 mg/mL streptomycin (Sigma-Aldrich), 2 mM L-glutamine, and 10 mg/mL blasticidin (Sigma-
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Aldrich) to select for Cas9 expressing cells. Cells were additionally cultured with 1.5 mg/mL puromy-
cin during selection of the transductants.
Western blot
RPE-1 TP53 wild-type and TP53KO cells were harvested in 100–200 uL of Laemmli buffer (120 mM
Tris 6.8 pH, 4%SDS, 20% glycerol). Protein concentrations were determined using a NanoDrop spec-
trophotometer (Thermo Scientific) at A280 nm. SDS-PAGE was performed with 35 mg of protein
lysates, the proteins were resolved on a precast NuPAGE Novex 4–12% Bis/Tris gradient gel (Invitro-
gen). Resolved proteins were transferred to a nitrocellulose membrane (GE Healthcare) and immuno-
blotted with the following antibodies at a 1/1,000 dilution: p53 (#554293, BD Biosciences) and
GAPDH (#MAB374, Merck Millipore).
Human cell line generation
RPE-1 wild-type cells were originally obtained from the ATCC cell repository by Professor Jonathon
Pines. They were routinely tested for mycoplasma and were authenticated using Affymetrix SNP6
copy number analysis. RPE-1 TP53KO cells were generated as described previously (Chiang et al.,
2016). The TP53 wild-type and TP53KO RPE-1 cells were transduced with a lentiviral vector encoding
Cas9 and a blasticidin resistance cassette to facilitate the isolation of Cas9-expressing clones. Limit-
ing dilution of the transduced population enabled isolation of monoclonal cell lines. Cas9 expression
was validated by western blot and Cas9 editing efficiency was assayed by transducing clones with a
lentiviral vector encoding GFP, BFP, and a sgRNA for GFP (obtained from Dr Emmanouil Metzako-
pian, UK Dementia Research Institute, Cambridge, UK). Transduced and non-transduced cells were
subjected to FACS sorting using an LSRFortessa (BD Biosciences) flow cytometer. The Cas9 editing
efficiency for each clone was calculated by comparing the percentage of BFP+ (i.e. edited) cells to
the GFP/BFP+ cells (i.e. total transduced population) using FlowJo.
Statistical software used
Statistical analyses were performed in Python (3.7.5), using the following packages in particular:
. MAGeCK (0.5.9.2)
. jupyterlab (1.1.4)
. matplotlib (3.1.1)
. seaborn (0.9.0)
. pandas (0.25.0)
. numpy (1.16.4)
. scipy (for t-tests & Fisher’s exact test, 1.3.0)
. scikit-learn (for PCA, 0.21.2)
. statsmodels (for linear regression and multiple testing correction, 0.10.1)
CRISPR screen re-analyses
Data files containing guide abundances were downloaded from https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE128210.
Supplementary file 5 lists the origins of the data. Where multiple timepoints were available, the
day 18 timepoint was used. Guides targeting genes not present in our DDR library were removed
from the abundance tables, and MAGeCK (0.5.9.2) was used to obtain significance values for deple-
tion and enrichment of genes. The command line arguments remove-zero-threshold=10 and
remove-zero=control were used.
LFC normalisation
LFCs were normalised by subtracting the mean of the olfactory receptor (OR) genes from all values,
and then dividing all values by the SD of the OR genes.
Resampling
To simulate smaller sequencing runs, guide abundances were resampled by N random draws using
the initial abundances as weights. N was set to yield expected median abundances ranging between
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10 and 1000. MAGeCK was used to obtain significance values as above. five replicate draws were
performed per sample.
Pathway analysis
Genes within the library were annotated according to KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathway. Selection of relevant pathways within the library was based on classifications by
Pearl et al. (2015). The enrichment of genes with p<0.05 in these pathways was evaluated using
Fisher’s exact test. Genes that were depleted over time, or enriched, were tested separately.
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days after which the sample was harvested.
. Supplementary file 3. MAGeCK Statistics. Results of all analyses performed with MAGeCK. An
Excel workbook with results divided by screen. The worksheet names match the screen names used
in the paper. Columns in each worksheet give the log2 fold change (‘lfc’), false discovery rate (‘fdr’), -
log10 FDR (‘fdr_log10’), p-value for enrichment (‘pos_p’) and p-value for depletion (‘neg_p’).
. Supplementary file 4. Enrichment of KEGG and GO Terms. A CSV that gives results of Fisher’s
exact test for enrichment of selected GO and KEGG terms. Each row gives the results for a particular
term. Genes that are present in the CRISPR library that match terms are listed in the ‘intersection’
column. Significance statistics for genes enriched or depleted in the screen are presented.
. Supplementary file 5. Data Sources. A TSV that maps the screen names used in this publication to
the identity of the original performers of the screen.
. Transparent reporting form
Data availability
Data files and scripts to produce Figures 2 and 3 are available from Dryad Digital Repository,
https://doi.org/10.5061/dryad.2fqz612kr.
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The following dataset was generated:
Author(s) Year Dataset title Dataset URL
Database and
Identifier
Bowden AR, Mor-
ales-Juarez DA,
Sczaniecka-Clift M,
Agudo MM, Lu-
kashchuk N, Tho-
mas JC, Jackson SP
2020 Parallel CRISPR-Cas9 screens clarify
impacts of p53 on screen
performance
https://doi.org/10.5061/
dryad.2fqz612kr
Dryad Digital
Repository, 10.5061/
dryad.2fqz612kr
The following previously published dataset was used:
Author(s) Year Dataset title Dataset URL
Database and
Identifier
Brown KR, Moffat J 2019 CRISPR screens are feasible in TP53
wild-type cells
https://www.ncbi.nlm.
nih.gov/geo/query/acc.
cgi?acc=GSE128210
NCBI Gene
Expression Omnibus,
GSE128210
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